文献速递前列腺癌男科与性医学

前列腺癌雄激素剥夺治疗相关抑郁的诊断与治疗中的种族差异

Racial Disparities in Diagnosis and Treatment of Depression Associated with Androgen Deprivation Therapy for Prostate Cancer.
PubMed 文献 · Urology · 2024-02-21

基于TriNetX健康记录网络2003—2023年数据,纳入93个医疗机构的78,313例接受雄激素剥夺治疗的前列腺癌患者,比较白人与黑人患者的抑郁诊断率和治疗率。接受雄激素剥夺治疗的患者发生抑郁的比值比其他患者高60%,确诊抑郁者中仅35%接受抗抑郁药治疗。白人患者抑郁诊断比值和一线抗抑郁药治疗比值均高于黑人患者。

要点

  • 接受雄激素剥夺治疗的前列腺癌患者发生抑郁的比值比其他患者高60%(9% vs 6%;OR 1.6;95%CI 1.5-1.7;P<.0001)。
  • 继发于雄激素剥夺治疗的抑郁患者中仅35%接受抗抑郁药治疗。
  • 白人患者抑郁诊断比值高于黑人患者(10% vs 8%;OR 1.3;95%CI 1.2-1.4;P<.001),一线抗抑郁药治疗比值亦更高(56% vs 48%;OR 1.4;95%CI 1.2-1.6;P<.001)。

核心结论

  • 本分析证实雄激素剥夺治疗与临床抑郁的发生存在显著关联,并凸显其医疗上治疗不足。
  • 研究发现抑郁识别与治疗存在显著种族差异。
  • 作者认为,考虑健康社会决定因素的常规筛查举措可能减轻这一差异。

研究设计与样本

  • 查询TriNetX健康记录网络2003—2023年前列腺癌接受雄激素剥夺治疗的患者。
  • 比较白人与黑人患者抑郁诊断率和治疗率的差异。
  • 单变量分析计算均值、比值比(OR)和t检验,报告95%置信区间(CI)。
  • 数据来自93个医疗机构,共78,313例接受雄激素剥夺治疗的前列腺癌患者。

主要发现

  • 接受雄激素剥夺治疗的患者发生抑郁的比值比其他患者高60%(9% vs 6%;OR 1.6;95%CI 1.5-1.7;P<.0001)。
  • 继发于雄激素剥夺治疗的抑郁患者中仅35%接受抗抑郁药治疗。
  • 开始雄激素剥夺治疗后,白人患者被诊断抑郁的比值比黑人患者高30%(10% vs 8%;OR 1.3;95%CI 1.2-1.4;P<.001)。
  • 白人患者接受一线抗抑郁药治疗的比值高于黑人患者(56% vs 48%;OR 1.4;95%CI 1.2-1.6;P<.001)。

临床怎么用

  • 作者认为,考虑健康社会决定因素的常规筛查举措可能减轻抑郁识别与治疗中的种族差异。

局限性

  • 本研究为回顾性设计。
  • 缺乏描述抑郁严重程度的数据,而抑郁严重程度可能与是否需要药物治疗相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze potential racial disparities in the diagnosis and management of depression associated with androgen deprivation therapy. METHODS: TriNetX health record network was queried for prostate cancer patients treated with androgen deprivation therapy from 2003-2023. Differences in rates of depression diagnosis and treatment were compared between White and Black patients. Means, odds ratios, and t tests were calculated in univariate analysis with 95% confidence intervals (CI). RESULTS: Data were queried from 93 health care organizations to yield 78,313 prostate cancer patients treated with androgen deprivation therapy. Patients on androgen deprivation therapy had 60% greater odds of developing depression vs other patients [9% vs 6%; odds ratio (OR) 1.6; 95% CI (1.5-1.7); P <.0001]. Of those with depression secondary to androgen deprivation therapy, only 35% were treated with antidepressants. After starting androgen deprivation therapy, White patients had 30% greater odds of being diagnosed with depression, compared to Black patients [10% vs 8%; OR 1.3; 95% CI (1.2-1.4); P <.001]. White patients also had higher odds of being treated with a first line antidepressant than Black patients [56% vs 48%; OR 1.4, 95% CI (1.2-1.6), P <.001]. CONCLUSION: This analysis confirms a significant association between androgen deprivation therapy and the development of clinical depression, and highlights its medical undertreatment. Importantly, our findings also indicate significant racial disparities in the identification and treatment of depression. Routine screening initiatives that account for social determinants of health may alleviate this disparity. Limitations of this study include retrospective design and lack of data describing severity of depression, which might correlate with need for medication.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Mandel AL, Simhal RK, Shah YB, et al. Racial Disparities in Diagnosis and Treatment of Depression Associated with Androgen Deprivation Therapy for Prostate Cancer. Urology. 2024. PMID: 38395075. doi:10.1016/j.urology.2024.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。